Clinical trial
Phase Ⅰ/Ⅱa Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Injection of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in Patients With Premature Ovarian Insufficiency (POI)
NCT07775391 is registered in ClinicalTrials.gov with Shenzhen Wingor Biotechnology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase Ⅰ/Ⅱa Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Injection of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in Patients With Premature Ovarian Insufficiency (POI)
- Lead sponsor
- Shenzhen Wingor Biotechnology Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- August 3, 2026
- Completion date
- August 2, 2029
- Enrollment
- 59 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
premature ovarian insufficiency